Results

1–10 of 11 results for Rishi P. Singh

12-Month Ocular Pharmacokinetic Study of EYP-1901 a Sustained-Release Intravitreal Formulation of the Tyrosine Kinase Inhibitor Vorolanib
Rishi P. Singh, MD
Annual Meeting Talks
2023
Results From Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Annual Meeting Talks
2024
Results from Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD
Updates from the Field
2024
12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial
Rishi P. Singh, MD
Updates from the Field
2022
Defining and Addressing Wet AMD Non-responders
Rishi P. Singh, MD
Updates from the Field
2019
Sustained Diabetic Retinopathy Severity Improvement With Intravitreal Aflibercept in DME: Post Hoc Analysis of VISTA and VIVID
Rishi P. Singh, MD
Annual Meeting Talks
2019
Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody RG7716 in Diabetic Macular Edema: 36-Week Results From the Phase 2 BOULEVARD Clinical Trial
Rishi P. Singh, MD
Annual Meeting Talks
2018
ASRS Presidents' Retina Young Investigators Award, Advancing Insights Into Diabetic Eye Disease, Rishi P. Singh, MD
Rishi P. Singh, MD
Annual Meeting Talks
2018
Remarkable Findings From Steroids for DME Studies
Rishi P. Singh, MD
Updates from the Field
2017
3D: Tips and Tricks to Maximize Your View and Experience
Rishi P. Singh, MD
Updates from the Field
2018